Get Your Own businessabc Wiki

Boost credibility, visibility, and discoverability

Last Updated: 2026

FibroGen

Rank#9822

Market Cap39.28M

CountryUnited States

Summary

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

History

FibroGen was founded in 1993 by Chief Executive Officer and Chair of the Board, Thomas Neff, to focus on the development of innovative therapies to treat anemia and fibrosis.

Mission

Our mission is to discover, develop, and commercialize novel therapies to treat anemia and fibrosis. We seek to bridge the gap between scientific innovation and patient outcome.

Vision

Our vision is to be the leader in the development and commercialization of novel therapies targeting anemia and fibrosis.

References

https://in.investing.com/equities/fibrogen-inc

https://finance.yahoo.com/quote/FGEN/profile?p=FGEN

https://www.crunchbase.com/organization/fibrogen

https://sec.report/CIK/0000921299

https://companiesmarketcap.com/

https://www.fibrogen.com

Leadership team

Mr. Enrique A. Conterno (CEO & Director)

Mr. Juan Graham (Chief Financial Officer)

Dr. Elias Kouchakji (Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance)

Products / Services

Biopharma, Biotechnology, Health Care, Therapeutics

Number of Employees

500 - 1000

Address

San Francisco, California, United States

Established

1993-01-01

Company Registration

SEC CIK number: 0000921299

Revenue

100M - 500M

Traded as

FGEN

Website

https://www.fibrogen.com

Social Media

Last Updated: 2026

Get Your Own businessabc Wiki

Boost credibility, visibility, and discoverability

Learn More

Last Updated: 2026

FibroGen

Rank#9822

Market Cap39.28M

CountryUnited States

Summary

History

FibroGen was founded in 1993 by Chief Executive Officer and Chair of the Board, Thomas Neff, to focus on the development of innovative therapies to treat anemia and fibrosis.

Mission

Our mission is to discover, develop, and commercialize novel therapies to treat anemia and fibrosis. We seek to bridge the gap between scientific innovation and patient outcome.

Vision

Our vision is to be the leader in the development and commercialization of novel therapies targeting anemia and fibrosis.

References

https://in.investing.com/equities/fibrogen-inc

https://finance.yahoo.com/quote/FGEN/profile?p=FGEN

https://www.crunchbase.com/organization/fibrogen

https://sec.report/CIK/0000921299

https://companiesmarketcap.com/

https://www.fibrogen.com

Leadership team

Mr. Enrique A. Conterno (CEO & Director)

Mr. Juan Graham (Chief Financial Officer)